August 22, 2022 by Chain Drug Review
Dr. Lawrence Tabak, NIH, performing the duties of the NIH Director issued the following statement on Dr. Anthony Fauci
Leading Headlines, Pharmacy

BETHESDA, Md. — Dr. Anthony Fauci announced on Monday he plans to step down in December from his role as director of the National Institute of Allergy and Infectious Diseases—a position he held for more than 35 years, through the AIDS and COVID pandemics—as well as his role of chief medical adviser to President Joe
August 10, 2021 by Chain Drug Review
NIH
Leading Headlines

ROCKVILLE, Md. – The National Institutes of Health’s (NIH) Dietary Supplement Label Database (DSLD) has been redesigned and modernized, making it easier for users to learn about and search for dietary supplement products sold in the United States. The DSLD captures all the information printed on nearly 130,000 labels of dietary supplements and is regularly updated to
July 15, 2020 by Chain Drug Review
1Day Sooner, COVID-19, Dr. Francis Collins, NIH
Leading Headlines, Pharmacy

NEW YORK — In an open letter to Dr. Francis Collins, director of the National Institutes of Health (NIH), 15 Nobel Laureates are joined by over one hundred prominent figures and over two thousand 1Day Sooner challenge volunteers in advocating for the potential of challenge trials to accelerate COVID-19 vaccine development. The signatories come from a
June 15, 2020 by Chain Drug Review
COVID-19, NIH
Leading Headlines, Pharmacy

WASHINGTON — The National Institutes of Health has launched a centralized, secure enclave to store and study vast amounts of medical record data from people diagnosed with coronavirus disease across the country. It is part of an effort, called the National COVID Cohort Collaborative (N3C) https://ncats.nih.gov/n3c/about, to help scientists analyze these data to understand the disease
April 24, 2020 by Chain Drug Review
Agilum', FDA, hydroxychloroquine (HCQ) i, NIH
Leading Headlines, Pharmacy

DEERFIELD BEACH, Fla. — The National Institutes of Health (NIH) released a statement this week warning against the use of hydroxychloroquine (HCQ) in combination with azithromycin. This conclusion mirrors Agilum Healthcare Intelligence’s real-world evidence published two weeks earlier on April 7th. Agilum was also pleased that the U.S. Food and Drug Administration (FDA) issued a
April 9, 2020 by Chain Drug Review
COVID-19, hydroxychloroquine, James Kiley, NIH
Pharmacy, Supplier News

NEW YORK — A clinical trial to evaluate the safety and effectiveness of hydroxychloroquine for the treatment of adults hospitalized with coronavirus disease 2019 (COVID-19) has begun, with the first participants now enrolled in Tennessee. The Outcomes Related to COVID-19 treated with hydroxychloroquine among In-patients with symptomatic Disease study, or ORCHID Study, is being conducted